{"product_id":"omnicell-pestle-analysis","title":"Omnicell PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE Analysis of Omnicell reveals how regulatory shifts, tech innovation in medication management, and global healthcare trends create both risks and growth levers for the company—insights ideal for investors and strategists. Ready-made and fully sourced, this report saves you time and powers smarter decisions. Purchase the full analysis to access detailed, actionable intelligence and downloadable charts for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpgovernment healthcare policies in the us and abroad shape hospital capital spending with hospitals expenditures at roughly billion directly affecting purchases of medication management supply chain automation.\u003e\n\u003cpchanges in reimbursement toward value-based care where of medicare payments tied to alternative models or free budgets for omnicell solutions.\u003e\n\u003cpby late federal allocations approaching billion for digital health infrastructure influence omnicell domestic growth strategy and product adoption timelines.\u003e\n\u003c\/pby\u003e\u003c\/pchanges\u003e\u003c\/pgovernment\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOmnicell depends on a global supply chain for components in its ADCs and robotics; in 2024 about 35% of its hardware-related procurement originated from Asia, exposing it to regional trade risks.\u003c\/p\u003e\n\u003cp\u003eTariffs or trade tensions—for example US-China tariff fluctuations that added up to 10–15% on electronics in past cycles—can raise production costs and delay deliveries, squeezing the 2024 gross margin of 38.7% on product revenue.\u003c\/p\u003e\n\u003cp\u003eManaging supplier diversification and tariff mitigation is critical to protect margins and meet demand across North American, EMEA and APAC markets where Omnicell reported FY2024 revenue of $1.3 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment focus on the opioid crisis and medication adherence—driven by 2023 US HHS initiatives reducing opioid prescriptions by 13% and CDC data showing 50% of patients nonadherent—boosts demand for Omnicell’s tracking and dispensing systems; automated dispensing growth projected at CAGR 8–10% through 2026 supports this market tailwind. Political pressure to cut medication errors (estimated 1.3M adverse events yearly in the US) accelerates adoption of AI-enabled solutions, and Omnicell aligns its roadmap to win government contracts and institutional partnerships, contributing to its 2024 revenues (approx. $1.2B) from hospital automation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical debates on drug pricing and transparency—highlighted by 2024 US proposals targeting middleman rebates and Medicare negotiation savings estimated up to $100B over 10 years—pressure pharmacy margins and the broader care chain.\u003c\/p\u003e\n\u003cp\u003eLegislation lowering prices drives pharmacies toward automation to cut costs; automated dispensing can reduce drug waste by up to 30% and labor costs by ~20% per industry reports.\u003c\/p\u003e\n\u003cp\u003eOmnicell markets inventory-management and med‑supply automation as tools to offset regulatory revenue pressure; its 2023 revenue of $993M underscores market relevance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory cuts pressure margins, impacting pharmacy ops\u003c\/li\u003e\n\u003cli\u003eAutomation reduces waste ~30% and labor ~20%\u003c\/li\u003e\n\u003cli\u003eOmnicell $993M revenue (2023) positions it as a mitigation vendor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Lobbying and Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmnicell actively lobbies regulators and pharmacy associations to influence pharmacy practice acts and automation standards, supporting broader clinical adoption of robotics; in 2024 Omnicell reported government affairs spending aligning with industry peers, while policy engagement helped secure pilot programs in over 120 health systems.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, participation in federal and state policy discussions remains central to Omnicell’s strategy, enabling alignment of reimbursement and safety rules that favor scalable deployment of its medication management platforms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy targets: pharmacy practice acts, automation standards\u003c\/li\u003e\n\u003cli\u003eImpact: pilots in 120+ health systems (2024)\u003c\/li\u003e\n\u003cli\u003eStrategy: active federal\/state policy engagement (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital automation boom: $90.5B capex, $3.2B digital funding, margins vs tariff risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppolitical drivers: us hospital capex and fy2024 omnicell revenue shape demand for automation medicare value-based payments federal digital health funding influence adoption of hardware procurement from asia potential tariff swings risk margins gross margin in opioid policy drug-pricing reforms push pharmacies toward cut labor\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital capex (2024)\u003c\/td\u003e\n\u003ctd\u003e$90.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare value-based share (2024)\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed digital health funding (2025)\u003c\/td\u003e\n\u003ctd\u003e$3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOmnicell FY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHardware spend from Asia (2024)\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct gross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e38.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff impact range\u003c\/td\u003e\n\u003ctd\u003e10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation benefits\u003c\/td\u003e\n\u003ctd\u003eWaste ↓30%, Labor ↓20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Omnicell across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trend-based insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise, visually segmented PESTLE summary for Omnicell that highlights regulatory, tech, and market risks—ready to drop into presentations, share across teams, and annotate with region-specific notes for faster strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Capital Expenditure Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe economic health of US hospital systems—operating margins averaged -0.4% in 2023 and liquidity days fell to ~145—directly limits capital for high-cost automation hardware, pressuring purchases.\u003c\/p\u003e\n\u003cp\u003eWith the Fed funds rate at ~5.25% in 2024 and tighter credit, many systems delay capex or favor leasing; healthcare equipment financing volume fell ~6% YoY in 2023.\u003c\/p\u003e\n\u003cp\u003eOmnicell tracks these macro signals and adjusts by offering flexible leasing, subscription models, and tailored payment terms to sustain institutional sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Labor Shortages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent shortages of pharmacists and pharmacy technicians—US Bureau of Labor Statistics projects pharmacist openings to grow 4% and pharmacy technician jobs by 4% through 2024–26 with vacancies up to 15–20% in some hospitals—drive demand for automation; Omnicell systems reduce manual labor and cut dispensing errors, improving labor productivity by reported 20–30% in client case studies. Investing in Omnicell yields measurable ROI via lower labor costs and reduced overtime, helping alleviate staff burnout and turnover. This economic necessity for efficiency is accelerating adoption of automated dispensing and supply-chain solutions through 2025, with market forecasts projecting hospital pharmacy automation growth above 8% CAGR. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising costs for raw materials, electronic components, and specialized labor have pressured Omnicell’s margins; semiconductor and component prices rose ~12% in 2024 while global labor costs in medical device manufacturing increased ~6%, squeezing gross margins below the company’s 2023 level of ~32%.\u003c\/p\u003e\n\u003cp\u003eTo counter inflation Omnicell must optimize supply chains, evidenced by peers achieving 3–5% cost reductions via dual sourcing and nearshoring, and consider modest price adjustments in service contracts where 2024 service revenue represented ~45% of total revenue.\u003c\/p\u003e\n\u003cp\u003eEconomic volatility demands disciplined cost management—targeting annual productivity gains of 4–6% and tighter SG\u0026amp;A control—to preserve profitability amid competitive pressures and rising COGS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift to Subscription Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOmnicell is shifting from one-time hardware sales to recurring Advanced Services and SaaS, with subscription revenue growing to 34% of total revenue by FY2024 and management targeting a majority-recurring mix by end-2025, improving predictability and multiple expansion.\u003c\/p\u003e\n\u003cp\u003eThis aligns with hospital budgeting trends favoring OPEX over CAPEX, supported by a 12% CAGR in Omnicell's recurring revenue (2021–2024) and reduced revenue volatility in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscription\/recurrent revenue 34% of FY2024 sales\u003c\/li\u003e\n\u003cli\u003eRecurring revenue CAGR 12% (2021–2024)\u003c\/li\u003e\n\u003cli\u003eTarget: majority-recurring mix by end-2025\u003c\/li\u003e\n\u003cli\u003eImproved cash-flow predictability and valuation upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Currency Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Omnicell expands in Europe and Asia, FX risk grows: FY2024 international revenue (~33% of total $1.7B) is sensitive to USD swings, with a 10% dollar strength potentially reducing reported revenue by ~3–4%.\u003c\/p\u003e\n\u003cp\u003eThe dollar's moves affect competitive pricing in local markets and margins; Omnicell reported using forward contracts and options, with $120M notional hedges in 2024 to stabilize cash flows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~33% of revenue from outside US (FY2024)\u003c\/li\u003e\n\u003cli\u003e10% USD appreciation could cut reported revenue ~3–4%\u003c\/li\u003e\n\u003cli\u003e$120M notional hedges in 2024 (forwards\/options)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnicell pivots to recurring revenue as margins face macro, FX and input pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds—US hospital margins -0.4% (2023), Fed funds ~5.25% (2024), and tighter credit—compress capex; Omnicell shifts to leasing\/subscriptions (34% recurring FY2024) and targets majority-recurring by 2025, while managing FX (33% intl revenue) and rising input costs (semis +12% 2024) to protect margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital margin (2023)\u003c\/td\u003e\n\u003ctd\u003e-0.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (2024)\u003c\/td\u003e\n\u003ctd\u003e~5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev (FY2024)\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eOmnicell PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Omnicell PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751200534905,"sku":"omnicell-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/omnicell-pestle-analysis.png?v=1772228802","url":"https:\/\/growthsharematrix.com\/products\/omnicell-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}